16. 5. 2017
Rare Diseases: AOP Orphan Pharmaceuticals AG invests in sustainable Research & Development
An interview with Dr Rudolf Widmann, CEO and Dr Christoph Klade, CSO about AOP Orphan’s commitment to sustainable innovation for the benefit of patients with rare diseases and Austria as a research location was published recently in CURE, a special edition insert for the Austrian newspaper “derStandard”.
To read the full article in German